Zai Lab of Shanghai in-licensed greater China rights to three MacroGenics immunoncology candidates in an agreement worth up to $165 million. Zai will make an upfront payment of $25 million and be responsible for up to $140 million in milestone payments, plus royalties. MacroGenics, a Maryland company, is a clinical-stage biopharma that discovers innovative monoclonal antibodies for cancer. In addition to developing its own novel products, Zai in-licenses innovative medicines for cancer, autoimmune and infectious diseases for China use.
Source: China Biotoday
